Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide
about
A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin-SCORE.Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trialsGalectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies.Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failurePredictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials.Five-year survival of patients with chronic systolic heart failure of ischemic and non-ischemic etiology: analysis of prognostic factors.The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA).Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model.Incorporating common biomarkers into the clinical management of heart failureAn economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial.Multivariate risk scores and patient outcomes in advanced heart failure.An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure.BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure.Incremental predictive value of natriuretic peptides for prognosis in the chronic stable heart failure population: a systematic review.Changes in Left Ventricular Ejection Fraction Predict Survival and Hospitalization in Heart Failure With Reduced Ejection FractionComparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA).Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA).Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients with stable coronary artery disease.The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*.Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA.Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure.Left atrial volume index in patients with heart failure and severely impaired left ventricular systolic function: the role of established echocardiographic parameters, circulating cystatin C and galectin-3.Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology.Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial.Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure.Enlarged waist combined with elevated triglycerides (hypertriglyceridemic waist phenotype) and HDL-cholesterol in patients with heart failure.Effect of ABCB1 genotype on pre- and post-cardiac transplantation plasma lipid concentrations.Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine I
P2860
Q30374980-7E2AAAB8-F586-4011-9872-D6E4185C370EQ33768602-571516E0-0D00-4C6A-9334-8260F2EC4AF3Q34269132-7C94BE2F-E38A-424F-B28A-AD44BFE1AC8BQ34308075-31DA40A5-941A-4C52-9C18-F07893D2E24CQ34504604-5AA1D319-C0C7-4AC7-A883-CB885DDA3B71Q34528187-C1B3BE51-ED62-44EA-9444-48CC5E390376Q34619812-A3FB4CE5-2517-423B-854A-27C58CE7677FQ34821843-FEAF724A-BF9B-4B4C-900A-56D657083120Q35531512-BF95EC2D-4A01-4858-98CA-D4EE10F274A0Q35750462-0D489E08-55DF-495F-A1F6-6BC148F1E677Q36954677-132EC833-75D1-4D48-A048-5C9372965742Q37347009-4B30333A-E748-435E-94CA-1D6262B87F13Q37484543-B7257AB0-5ED0-4DB3-895D-4748755C1D9AQ37929862-F73866D3-AB46-4515-8A95-1A40F4FC9A86Q38174653-370FB025-56CF-45D4-8CEC-4ECD63F30999Q38225445-88549631-B22E-42BE-BA7E-4FD73DC83ED5Q38239624-47729C02-12E9-48E8-966A-674CCB585254Q38387268-5E85F727-C32E-42E0-A266-23DA7C371319Q41255054-9F642E91-FBE2-43D9-808C-E670517189F9Q42101882-502F2F54-CF66-43FC-B601-2B3A68B49D8BQ43054647-58D4D6D8-25B7-4EB1-8A99-6170DBAF008AQ43188342-95B2072D-6430-4DB9-B4D5-F9EA406936E0Q44694136-D235A1E4-59F5-493B-A1B3-BB9A0EC4F525Q46677502-61EFEDBA-2DB4-4725-B8C9-D9CF716CEFCBQ46927699-D24C28F3-3D0B-465B-AE9E-049B45B327F1Q47281852-AF4E518E-135A-4DE7-8914-1483ECF4317AQ47920631-306FAA87-C764-457B-A0A9-C13BC1473434Q48084328-A705C5E4-9939-4201-99E2-EBF63A0BBD1DQ48677667-81A6BBFA-FDB6-4382-9B95-D8F4AD41CDA7Q49022238-559BE46C-7EDC-455D-87D8-7FC31AD8C62CQ49931164-5848075E-DF4C-4062-B63E-010C7CE44345Q51070512-EE4C9738-8205-4EA5-8921-111608B26465Q51375856-E699B079-5BEA-496B-9A25-8D4F776EEC6EQ57396192-795815B6-1CF6-4995-BDBC-47C56B7EFA08
P2860
Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Predictors of fatal and non-fa ...... pro B-type natriuretic peptide
@en
Predictors of fatal and non-fa ...... ro B-type natriuretic peptide.
@nl
type
label
Predictors of fatal and non-fa ...... pro B-type natriuretic peptide
@en
Predictors of fatal and non-fa ...... ro B-type natriuretic peptide.
@nl
prefLabel
Predictors of fatal and non-fa ...... pro B-type natriuretic peptide
@en
Predictors of fatal and non-fa ...... ro B-type natriuretic peptide.
@nl
P2093
P2860
P356
P1476
Predictors of fatal and non-fa ...... pro B-type natriuretic peptide
@en
P2093
Ake Hjalmarson
CORONA Study Group
Finn Waagstein
Hans Wedel
Jan H Cornel
Johan Vanhaecke
John G F Cleland
John J V McMurray
John Wikstrand
Magnus Lindberg
P2860
P304
P356
10.1093/EURJHF/HFN046
P577
2009-01-24T00:00:00Z